Diplomat in the First Quarter: Profit Recovered, Customers and Caesarea Still Consume Cash

Diplomat opened 2026 with a quarter that looks better than the end of 2025 implied: revenue rose 2.7%, operating profit rose 18.0%, and operating cash flow jumped to NIS 46.3 million after a comparable quarter that barely generated operating cash. But that improvement still does not close the question left open after the previous annual analysis: whether the company's growth is again turning into available cash, or still leaning on customer credit, inventory, leases and logistics investment. The first-quarter answer is mixed, but sharper. Profit improved, mainly in Israel, and inventory fell from year-end 2025, yet customer balances rose, the average customer-credit gap versus supplier credit widened, and Caesarea absorbed tens of millions of shekels more. So the quarter improves the 2026 starting point, but it does not turn the company into a simple net-profit story. The next proof points are collection pace, further inventory release without hurting sales, Caesarea's timetable, and whether Mexico remains a strategic option or becomes another capital use before the balance sheet is truly free.

A Business Built on Volume, Customer Credit and Shelf Access

Diplomat is not just an importer of brands. It is an FMCG distribution platform that connects global and local suppliers with thousands of points of sale in Israel and abroad. The economics of this business are built on volume, shelf access, logistics, inventory availability and trade credit. Margins are not especially wide, so a small shift in gross margin, customer days or supplier financing can change the quality of the whole quarter.

The business map for the quarter is straightforward. Israel generates roughly 64% of revenue and remains the main profit pool. South Africa is the second-largest market, but moved to an operating loss this quarter. Georgia is still loss-making, New Zealand continues to generate low profit despite local-currency growth, and Cyprus is a smaller but cleaner improvement point. That means the consolidated headline still hides heavy dependence on Israel and on the company's ability to preserve pricing, service and inventory there without stretching customer credit too far.

That context matters because 2025 already identified the active bottleneck: revenue and profit grew, but working capital consumed cash and the Caesarea logistics center became a real capital user. The first quarter does not erase that problem. It gives the company time and a better starting point, mainly because operating cash flow became meaningful again, but it still does not show that the cash model can work without financing support.

The Profit Recovery Came Mostly From Israel, Not the Whole Platform

The most positive number this quarter is not sales growth, but what happened to profitability. Revenue was NIS 900.4 million versus NIS 877.0 million in the comparable quarter, up 2.7%. Gross profit rose faster, to NIS 204.9 million, and gross margin rose to 22.8% from 22.1%. Operating profit rose to NIS 39.9 million, with an operating margin of 4.4% versus 3.9% in the comparable quarter.

The company attributes the gross-margin improvement to sales mix. That is positive, but not every segment contributed in the same way. Israel increased revenue by 4.6% and lifted operating profit to NIS 37.5 million from NIS 31.1 million. Cyprus grew faster, but remains small. South Africa, by contrast, declined to NIS 150.1 million of revenue and moved to an operating loss of NIS 1.1 million, while Georgia remained loss-making despite some improvement. New Zealand, a key yellow flag in 2025, increased reported revenue to NIS 63.5 million, but operating profit fell to NIS 0.8 million.

The segment read is sharper than the consolidated line: the quarter looks good mainly because Israel worked better. That is not a weakness by itself, because Israel is the group's natural core, but it means the improvement still does not prove that the full international platform has returned to value creation. New Zealand revenue rose 14.7% in local currency, and Cyprus rose 27.8%, but South Africa fell 7.7% in local currency. Local growth in small or weak markets is not enough if it does not generate stable operating profit.

Profit quality is also somewhat better than the finance line suggests. Finance expenses included a NIS 7 million provision related to the Neve Pharma mediation process. Without that provision, finance expenses would have declined by roughly NIS 5.5 million, mainly because of lower option remeasurement and FX expenses. So the NIS 20.8 million net profit is not being carried by an easy financing item. The opposite is closer to the truth: the quarter carries a legal expense that suppresses reported profit, while the dispute itself remains noise that can continue to absorb management and cash attention.

Cash Flow Improved, but Flexibility Has Not Fully Returned

Operating cash flow of NIS 46.3 million versus NIS 4.3 million in the comparable quarter is a real change. It mainly came from better working-capital behavior: changes in assets and liabilities consumed only NIS 2.7 million this quarter, compared with NIS 40.9 million in the comparable quarter. Inventory contributed NIS 23.4 million to cash flow, an early sign that the company can release part of the cash absorbed at the end of 2025.

But operating cash flow must be separated from cash flexibility after the quarter's actual cash uses. The bridge below checks what remains after operating cash flow, net investing cash flow and lease principal repayment. It is not normalized cash generation before investment, but a test of what remains after the real cash uses of the quarter.

After NIS 40.7 million of net investing cash use and NIS 18.8 million of lease principal repayment, the quarter was still short by roughly NIS 13.3 million before new credit. That does not indicate acute pressure, because cash rose to NIS 69.6 million and the company drew net short- and long-term credit, but it does explain why the strong quarter does not end the discussion. Investing cash flow included NIS 35.3 million of property and equipment purchases, mainly Caesarea, and another NIS 6.1 million of intangible investment. At the same time, the company declared a NIS 20 million dividend in March, paid in April, and on May 28 declared another NIS 10 million dividend.

Working capital explains this tension better than any income-statement line. Customer balances rose to NIS 523.7 million from NIS 501.9 million at the end of 2025, while inventory declined to NIS 540.3 million from NIS 561.0 million. On an average basis, customer credit rose to NIS 512.8 million from NIS 466.8 million in the comparable quarter, while supplier credit rose only to NIS 337.6 million from NIS 321.6 million. The gap between the two widened to roughly NIS 175.1 million from NIS 145.2 million.

This is exactly where the market can read the quarter too quickly. Versus March 2025, short-term credit is still lower, mainly because of the July 2025 equity raise. Versus year-end 2025, it already rose by roughly NIS 30 million, mainly because of Caesarea, South Africa and working capital. The earlier equity raise still helps, but it did not turn the model into one that finances all growth internally.

Caesarea, Mexico and Georgia Keep 2026 as a Proof Year

Caesarea is the clearest capital use inside the quarter. Property and equipment rose to NIS 248.3 million, mainly because of roughly NIS 35 million of investment in the logistics-center project during the quarter, and versus March 2025 the cumulative project investment explains roughly NIS 79 million of the increase. In addition, other long-term assets include roughly NIS 40 million of advances to the Caesarea property company in lieu of future lease payments. This is not just a one-time investment before an efficiency gain. It is a layer of cash, leases and euro hedging that must begin paying back through efficiency, volume and utilization.

Mexico adds a larger growth option, but also a larger funding question. The non-binding memorandum of understanding covers the purchase of 60% of two distribution companies in Mexico, with estimated consideration of roughly $80 million, adjustment mechanisms, earn-outs, and CALL and PUT options over the remaining holdings. The parties set a period of up to 120 days to form binding agreements, subject to due diligence, approvals and other conditions. In business terms, the company has a strategic option, not a closed transaction. If it advances, the question will not only be whether Mexico is attractive, but what funding structure it brings and how much it adds to the group's capital needs.

Georgia is a smaller flag, but should not be ignored. The Georgian subsidiary received a bank waiver on March 31, 2026 for non-compliance with the interest-coverage ratio, with testing deferred by 12 months. The company expects to comply with the financial covenants, and this is not a group-level stress event, but it is a reminder that the international platform is uneven. Where a segment is still operating at a loss, even a small local covenant can move from legal noise to a funding point.

The Nutrilon recall, as of the report date, had no material impact on activity. It could matter only if there is a very material and prolonged decline or an expansion to additional products. So it does not change the quarter's thesis, but remains a commercial checkpoint.

Conclusion

The first quarter of 2026 improves the company's starting position, but it does not change what investors need to measure in the next reports. Operating profitability is rising again, operating cash flow improved, and Israel shows that it can still carry the group. Against that, the model still consumes capital through customers, Caesarea, leases and dividends, while the international activity remains uneven.

The current read is more positive than at the end of 2025, but not clear enough to rely only on net profit. For the interpretation to improve meaningfully, the company needs to show over the next two to four quarters that the inventory decline was not one-off, customers are not expanding faster than suppliers, Caesarea does not push another rise in short-term credit, and Mexico, if it advances, arrives in a structure that does not consume the balance-sheet flexibility that has just been rebuilt. The strongest counter-thesis is that this quarter already proves enough: profit rose, operating cash flow returned, and Caesarea and Mexico are exactly the investments a distributor needs to expand the platform. That is a reasonable argument, but it will become stronger only if the next quarters show cash left after investment, not only profit that arrives before balance-sheet uses.